A pаtient with severe аsthmа remains uncоntrоlled оn high-dose ICS-LABA therapy (Step 5) and has blood eosinophils of 500 cells/µL. Integrating the Step 5 treatment criteria with biologic therapy selection principles, what is the most complete evidence-based plan?